RGNX
Regenxbio·NASDAQ
--
--(--)
--
--(--)
6.15 / 10
Outperform
Fund-flow analysis shows a strong score of 7.84/10, with positive trends across block, medium, large, and extra-large orders, indicating robust institutional demand. Only small orders show a mild negative bias, a pattern often seen when larger players accumulate without retail participation. Analyst coverage is sparse (one active analyst) but uniformly bullish (Strong Buy rating), and the sentiment score of 6.15/10 aligns with the fund-flow data. Together, these elements suggest that both money and expert opinion are tilting in favor of RGNX, despite limited coverage.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-29
InstitutionChardan Capital
Times predicted7
Historical Win Rate42.9%
Is money flowing into or out of RGNX?
- RGNX holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.15/10 (Outperform).
